Literature DB >> 25253293

Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis.

Ana V Nikolić1, Goran G Bačić, Marko Ž Daković, Slobodan Đ Lavrnić, Vidosava M Rakočević Stojanović, Ivana Z Basta, Dragana V Lavrnić.   

Abstract

Myasthenia gravis (MG) associated with anti-muscle-specific tyrosine kinase (MuSK) antibodies differs in many aspects from typical presentation of acetylcholine receptor (AChR)-positive MG. Myopathy and muscle atrophy are observed in MuSK-positive MG patients, unlike AChR-positive patients with MG. That is why the aim of this study was to assess the presence of myopathy and muscle atrophy as well as the tongue lipid composition in our cohort of MuSK-positive MG patients. Clinical examination, electromyography (EMG) and proton magnetic resonance spectroscopy were performed in 31 MuSK-positive and 28 AChR-positive MG patients. Myopathic EMG was more frequent in MuSK compared to AChR MG patients. In AChR MG patients, myopathic EMG in facial muscles was more frequent after long-term corticosteroid treatment, which was not the case with MuSK-positive MG patients. Facial and/or tongue muscle atrophy was registered in 23 % of MuSK MG patients. Longer disease duration was observed in patients with clinical signs of tongue and/or facial muscle atrophy compared to those with normal tongue muscle. Intramyocellular lipid deposition in the tongue was present in 85.2 % of MuSK and 20 % of AChR MG patients. Female MuSK MG patients had more frequently electrophysiological signs of myopathy on the facial muscles and signs of intramyocellular lipid deposition in the tongue, compared to male patients with MuSK-positive MG. Myopathy, muscle atrophy and intramyocellular lipid deposition in the tongue are more frequent in MuSK-positive compared to AChR-positive MG patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253293     DOI: 10.1007/s13760-014-0364-1

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  4 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.

Authors:  Kazushiro Takata; Panos Stathopoulos; Michelangelo Cao; Marina Mané-Damas; Miriam L Fichtner; Erik S Benotti; Leslie Jacobson; Patrick Waters; Sarosh R Irani; Pilar Martinez-Martinez; David Beeson; Mario Losen; Angela Vincent; Richard J Nowak; Kevin C O'Connor
Journal:  JCI Insight       Date:  2019-06-20

3.  Extraocular Muscle Atrophy in Myasthenia Gravis.

Authors:  Radhakrishna Pedapati; Uma Ravishankar; Philo Hazeena; Sundar Shanmugam; Anupama Chandrasekharan; Shankar Venkatasubramanian
Journal:  Ann Indian Acad Neurol       Date:  2022-04-07       Impact factor: 1.714

4.  The feasibility of quantitative MRI of extra-ocular muscles in myasthenia gravis and Graves' orbitopathy.

Authors:  Kevin R Keene; Luc van Vught; Nienke M van de Velde; Isabeau A Ciggaar; Irene C Notting; Stijn W Genders; Jan J G M Verschuuren; Martijn R Tannemaat; Hermien E Kan; Jan-Willem M Beenakker
Journal:  NMR Biomed       Date:  2020-09-07       Impact factor: 4.044

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.